Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Date publication

août 2019

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31445454

Résumé

We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study.

Mots clés

Antibody-dependent cell-mediated cytotoxicity, Biosimilar, Long-term extension study, SB3, Trastuzumab

Référence

Eur. J. Cancer. 2019 Aug 21;120:1-9